ctDNA Monitoring After Pancreatic Cancer Surgery (K-4CARE Lite Study)

Official title

A Prospective Observational Study of Circulating Tumor DNA Dynamic Monitoring Using K-4CARE Lite Platform After Curative Resection of Pancreatic Cancer

Overview

Pancreatic ductal adenocarcinoma (PDAC) carries one of the worst prognoses among solid tumors. Even after curative-intent resection, 70-80% of patients recur within two years. Current post-operative surveillance relies on computed tomography (CT) imaging and the serum tumor marker CA 19-9, but both have limited sensitivity for detecting microscopic residual disease. This single-center, prospective observational study evaluates the use of the K-4CARE Lite platform-a tumor-informed plus tumor-agnostic circulating tumor DNA (ctDNA) assay with a limit of detection of 0.005%-for dynamic monitoring of minimal residual disease (MRD) in patients with resected PDAC. Thirty adult patients who have undergone R0 or R1 (margin \<1 mm) resection at Linkou Chang Gung Memorial Hospital will be enrolled over 24 months. Each participant will provide one baseline tumor tissue sample (formalin-fixed paraffin-embedded) and three serial blood samples at three pre-specified study timepoints: Timepoint 1 (Week 4 to Week 10 after surgery, before adjuvant chemotherapy); Timepoint 2 (12 weeks after Timepoint 1, approximately 3 months into adjuvant chemotherapy); and Timepoint 3 (at completion of adjuvant chemotherapy, approximately Month 6 after surgery). A fourth long-term follow-up phase (Timepoint 4) collects results from patient-funded ctDNA testing performed as part of routine care. The primary outcome is the cumulative MRD detection rate across the three pre-specified post-surgical timepoints (Timepoint 1, Timepoint 2, and Timepoint 3). Secondary outcomes include the association between ctDNA status and disease-free survival (DFS) and overall survival (OS), molecular clearance rate at Timepoint 3, lead time of molecular relapse over imaging, and platform performance. ctDNA results are reported back to the treating physician for reference but do not mandate treatment changes-all clinical decisions remain at the physician's discretion per standard guidelines. This study aims to generate the prospective evidence base needed to design future ctDNA-guided interventional trials in pancreatic cancer.

Detailed description

BACKGROUND Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal solid tumors. Even after curative resection, 70-80% of patients relapse within 2 years. Conventional surveillance with CT imaging and serum CA 19-9 detects recurrence only after macroscopic tumor burden has accumulated, missing the window for early intervention. Circulating tumor DNA (ctDNA) has emerged as a sensitive biomarker for minimal residual disease (MRD) in colorectal and lung cancers, but standardized prospective ctDNA monitoring data in pancreatic cancer remain limited.

PLATFORM

K-4CARE Lite (Gene Solutions JSC, Ho Chi Minh City, Vietnam) is a comprehensive genomic profiling platform combining:

* 515-gene DNA panel for baseline tissue profiling * Up to 50 personalized tumor-informed tracking variants for liquid biopsy * 113-gene gastrointestinal tumor-agnostic panel as a parallel tumor-agnostic track * Hybrid capture sequencing at 5,000-10,000X depth on plasma, 200X on tissue * Limit of detection: 0.005% variant allele frequency (VAF) * Buffy coat / white blood cell sequencing in parallel to filter clonal hematopoiesis of indeterminate potential (CHIP) and germline variants * Reports homologous recombination deficiency (HRD), tumor mutational burden (TMB), microsatellite instability (MSI) status * First report turnaround: approximately 6 days

DESIGN Single-center, prospective, non-interventional observational cohort study at Linkou Chang Gung Memorial Hospital. ctDNA results are returned to the treating physician for reference but do not mandate any treatment change; all therapeutic decisions follow standard adjuvant chemotherapy practice and physician discretion.

POPULATION N = 30 adults (aged 20 years or older) with histologically confirmed PDAC who have undergone R0 or R1 (margin close \<1 mm) curative resection (pancreaticoduodenectomy, distal pancreatectomy, or total pancreatectomy), with post-operative pathologic stage at least pT1 N0 or any N1+, no radiologic evidence of residual or distant disease within 4 weeks before enrollment, and intent to receive adjuvant chemotherapy.

SAMPLING TIMELINE

* Screening: Week 4 to Week 12 after surgery; informed consent * Baseline: Formalin-fixed paraffin-embedded (FFPE) tumor tissue and buffy coat (drawn at Timepoint 1) * Timepoint 1 (mandatory): Week 4 to Week 10 after surgery, before first adjuvant chemotherapy dose; 20 mL whole blood * Timepoint 2 (mandatory): 12 weeks after Timepoint 1 (approximately 3 months into chemotherapy); 20 mL whole blood * Timepoint 3 (mandatory): At completion of adjuvant chemotherapy or premature termination (approximately Month 6 after surgery); 20 mL whole blood * Timepoint 4 (passive data collection only): Long-term follow-up after Timepoint 3; the study does not arrange or fund ctDNA testing in this phase. If a participant elects to undergo ctDNA testing as part of self-funded routine care, the study collects those results.

PRIMARY OUTCOME Cumulative MRD detection rate across the three pre-specified post-surgical timepoints (Timepoint 1, Timepoint 2, and Timepoint 3), defined as the proportion of participants with at least one tracking mutation detected at variant allele frequency above the K-4CARE Lite platform's limit of detection at one or more timepoints.

SECONDARY OUTCOMES

* Disease-free survival (DFS): From surgery to first radiologic or pathologic recurrence or death from any cause * Overall survival (OS): From surgery to death from any cause * Molecular clearance rate at Timepoint 3: Proportion of participants with negative ctDNA result at Timepoint 3 (newly cleared or persistently negative) * Lead time of molecular relapse: Interval from first ctDNA conversion (negative to positive) to radiologic recurrence * VAF kinetics from Timepoint 1 through Timepoint 3 (slope: rising, falling, stable) * Platform performance: Assay success rate and turnaround time from sample receipt to report * Single-timepoint MRD detection rate at Timepoint 1 (reported separately for cross-study comparison with prior single-timepoint PDAC ctDNA literature)

EXPLORATORY OUTCOMES

* Correlation of baseline HRD, TMB, and MSI with ctDNA dynamics * Concordance of ctDNA monitoring with CA 19-9 trajectory (Cohen's kappa) * Frequency and types of newly emerging resistance mutations during follow-up

STATISTICAL METHODS Primarily descriptive. MRD detection rate reported as percentage with 95% Wilson confidence interval. Survival analyses by Kaplan-Meier with log-rank tests, exploratory given the limited sample size. Categorical comparisons by Fisher's exact test. Continuous comparisons by Wilcoxon rank-sum test. Cox proportional hazards regression limited to 2 to 3 covariates given the sample size. Analyses in R (version 4.0 or higher) or SAS (version 9.4 or higher); two-sided p \< 0.05. Missing data not imputed.

FUNDING Timepoint 1 through Timepoint 3 ctDNA testing is funded by the principal investigator's intramural Body of Medical Research Project (BMRP) grant from Chang Gung Memorial Hospital. Gene Solutions provides the testing service only and has no role in study design, data analysis, or publication decisions. Timepoint 4 self-funded testing by participants is not reimbursed by the study.

SAMPLE LOGISTICS Samples are received in Taiwan at NEWCL and forwarded to Gene Solutions JSC, Ho Chi Minh City, Vietnam, for sequencing. Specimens carry a study code only; no identifiable patient information accompanies the sample.

Primary outcome measures

• Cumulative Minimal Residual Disease (MRD) Detection Rate Across Three Post-Surgical Timepoints [Time frame: From Timepoint 1 (Week 4 to Week 10 after surgery) through Timepoint 3 (approximately Month 6 after surgery, at completion of adjuvant chemotherapy), spanning up to 8 months per participant.]

Secondary outcome measures (5)

• ctDNA Molecular Clearance Rate at Timepoint 3 (End of Adjuvant Chemotherapy) [Time frame: At Timepoint 3, defined as completion of adjuvant chemotherapy (approximately Month 6 after surgery) or earlier termination.]
• ctDNA Variant Allele Frequency (VAF) Kinetics During Adjuvant Treatment [Time frame: From Timepoint 1 (Week 4 to Week 10 after surgery) through Timepoint 3 (approximately Month 6 after surgery, at completion of adjuvant chemotherapy), spanning up to 8 months per participant.]
• Disease-Free Survival (DFS) [Time frame: From date of surgery up to Month 36 (last enrolled participant followed for at least 12 months after Timepoint 3)]
• Overall Survival (OS) [Time frame: From date of surgery up to Month 36.]
• Lead Time of Molecular Relapse Over Imaging [Time frame: From Timepoint 1 (Week 4 to Week 10 after surgery) to end of follow-up, up to Month 36]

Eligibility criteria

Inclusion criteria

• Age 20 years or older
• Histologically confirmed pancreatic ductal adenocarcinoma (PDAC), including its histological subtypes
• Has undergone curative-intent resection (R0 or R1, defined as margin <1 mm), via pancreaticoduodenectomy, distal pancreatectomy, or total pancreatectomy
• Post-operative pathologic stage at least pT1, with N0 or N1 or higher
• Computed tomography (CT) or magnetic resonance imaging (MRI) within 4 weeks before enrollment confirming no evidence of residual tumor and no distant metastasis
• Intent to receive adjuvant chemotherapy
• Sufficient surgical FFPE tumor tissue available for genomic sequencing
• Able to understand and provide signed informed consent
• Patients with or without prior neoadjuvant chemotherapy are both eligible

Exclusion criteria

• Post-operative pathologic stage IV (distant metastasis), or R2 resection
• Concurrent active primary malignancy (except cured non-melanoma skin cancer or carcinoma in situ within the past 5 years)
• Severe post-operative complications precluding initiation of adjuvant chemotherapy within 12 weeks
• Receipt of post-operative radiation therapy
• Known hematologic disease or myeloproliferative disorder that may significantly affect ctDNA assay accuracy
• Pregnant or breastfeeding women
• Unable to comply with the protocol-specified blood draw schedule

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Observational model

Cohort

Study locations

Taiwan · 1 center

• Linkou Chang Gung Memorial Hospital — Taoyuan

Publications

• Pascual J, Attard G, Bidard FC, Curigliano G, De Mattos-Arruda L, Diehn M, Italiano A, Lindberg J, Merker JD, Montagut C, Normanno N, Pantel K, Pentheroudakis G, Popat S, Reis-Filho JS, Tie J, Seoane J, Tarazona N, Yoshino T, Turner NC. ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group. Ann Oncol. 2022 PMID 35809752
• Conroy T, Hammel P, Hebbar M, Ben Abdelghani M, Wei AC, Raoul JL, Chone L, Francois E, Artru P, Biagi JJ, Lecomte T, Assenat E, Faroux R, Ychou M, Volet J, Sauvanet A, Breysacher G, Di Fiore F, Cripps C, Kavan P, Texereau P, Bouhier-Leporrier K, Khemissa-Akouz F, Legoux JL, Juzyna B, Gourgou S, O'Callaghan CJ, Jouffroy-Zeller C, Rat P, Malka D, Castan F, Bachet JB; Canadian Cancer Trials Group and PMID 30575490
• Kobayashi S, Nakamura Y, Hashimoto T, Bando H, Oki E, Karasaki T, Horinouchi H, Ozaki Y, Iwata H, Kato T, Miyake H, Ohba A, Ikeda M, Chiyoda T, Hasegawa K, Fujisawa T, Matsuura K, Namikawa K, Yajima S, Yoshino T, Hasegawa K. Japan society of clinical oncology position paper on appropriate clinical use of molecular residual disease (MRD) testing. Int J Clin Oncol. 2025 Apr;30(4):605-654. doi: 10.10 PMID 39920551
• Borges FC, Pinto MS, Borges MF, Joao AA, Francisco E, Sousa M, Aral M, Oliveira V, Cunha JF, Mehrabi A, Berchtold C, Goncalves G, Bailey P, Buchler MW. The Role of Circulating Tumor DNA in Surgical Management of Pancreatic Cancer: Systematic Review and Meta-analysis. Ann Surg. 2026 Feb 16. doi: 10.1097/SLA.0000000000007036. Online ahead of print. PMID 41696920
• Bernard V, Kim DU, San Lucas FA, Castillo J, Allenson K, Mulu FC, Stephens BM, Huang J, Semaan A, Guerrero PA, Kamyabi N, Zhao J, Hurd MW, Koay EJ, Taniguchi CM, Herman JM, Javle M, Wolff R, Katz M, Varadhachary G, Maitra A, Alvarez HA. Circulating Nucleic Acids Are Associated With Outcomes of Patients With Pancreatic Cancer. Gastroenterology. 2019 Jan;156(1):108-118.e4. doi: 10.1053/j.gastro.2018 PMID 30240661
• Pietrasz D, Pecuchet N, Garlan F, Didelot A, Dubreuil O, Doat S, Imbert-Bismut F, Karoui M, Vaillant JC, Taly V, Laurent-Puig P, Bachet JB. Plasma Circulating Tumor DNA in Pancreatic Cancer Patients Is a Prognostic Marker. Clin Cancer Res. 2017 Jan 1;23(1):116-123. doi: 10.1158/1078-0432.CCR-16-0806. Epub 2016 Dec 19. PMID 27993964
• Lee B, Lipton L, Cohen J, Tie J, Javed AA, Li L, Goldstein D, Burge M, Cooray P, Nagrial A, Tebbutt NC, Thomson B, Nikfarjam M, Harris M, Haydon A, Lawrence B, Tai DWM, Simons K, Lennon AM, Wolfgang CL, Tomasetti C, Papadopoulos N, Kinzler KW, Vogelstein B, Gibbs P. Circulating tumor DNA as a potential marker of adjuvant chemotherapy benefit following surgery for localized pancreatic cancer. Ann O PMID 31250894
• Groot VP, Mosier S, Javed AA, Teinor JA, Gemenetzis G, Ding D, Haley LM, Yu J, Burkhart RA, Hasanain A, Debeljak M, Kamiyama H, Narang A, Laheru DA, Zheng L, Lin MT, Gocke CD, Fishman EK, Hruban RH, Goggins MG, Molenaar IQ, Cameron JL, Weiss MJ, Velculescu VE, He J, Wolfgang CL, Eshleman JR. Circulating Tumor DNA as a Clinical Test in Resected Pancreatic Cancer. Clin Cancer Res. 2019 Aug 15;25(16) PMID 31142500

Identifiers

NCT: NCT07597252 · K4CARE-Lite-PDAC-2026 · Chang Gung Memorial Hospital

Primary sources (government registries)

• ClinicalTrials.gov (US NIH)

View this study on ClinicalTrials.gov ↗